Common Cold Viruses Becoming Deadly; polyDNA Recommends Gene-Eden-VIR to Target Latent Viruses
Rochester, NY (PRWEB) November 05, 2013 -- The adenovirus family of viruses normally causes the common cold. These viruses were once thought to do little more than cause symptoms, such as a harsh cough, an upset stomach, and diarrhea. However, researchers report that these “highly contagious adenoviruses are doing more than just making people feel miserable (1).”
Some adenoviruses can kill.
“The term "killer cold virus" was applied to a new strain of Adenovirus termed adenovirus 14 or Ad14 that appeared in several outbreaks (2005, 2007, 2008 and 2009-10 in Ireland) and that caused severe pneumonia and deaths in several different groups of individuals. This term was used because, in most people, adenoviruses cause symptoms of the common cold, not severe pneumonia or death. Investigations done by state and city health authorities, the U.S. Air Force, and CDC during several outbreaks showed that Ad14 is a … emerging serotype of adenovirus that can cause severe and sometimes fatal respiratory disease in anyone, including healthy adults (2).” This information was published in an article on Medicinenet.com.
What kinds of symptoms are normally associated with adenovirus 14 infections?
“Adenovirus 14 infections usually begin with cold symptoms such as a cough, ‘runny nose,’ and mild fever and possibly throat irritation. The majority of infected people have these symptoms for several days (about three to five days), and then the infection clears without any medical treatment. However, with some individuals, infection with the adenovirus 14 strain…progresses past three to five days (and causes) additional symptoms. These symptoms may include diarrhea, bronchitis, eye infections, bladder infection, rash, high fevers, pneumonia, and shortness of breath (2).”
polyDNA, therefore, recommends Gene-Eden-VIR to those who want to help their immune systems target latent adenoviruses. This antiviral remedy recently went through a post-marketing clinical study in which participants “reported no side effects after taking Gene-Eden-VIR (3).” The study authors wrote that “We observed a statistically significant decrease in the severity, duration, and frequency of (viral) symptoms (3).”
Gene-Eden-VIR was designed to help the immune system target latent viruses. In fact, Gene-Eden-VIR was shown to be safe and effective in a recent post-marketing clinical study. That study was published on August 21, 2013 in the journal Pharmacology & Pharmacy (3). The study reports that the natural product Gene-Eden-VIR safely and effectively decreases symptoms in individuals infected with latent viruses (3).
Study authors wrote that “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms (3).”
Mike Evans of polyDNA said, “Gene-Eden-VIR helps the immune system specifically target the latent form of many different ciruses, which is something no other product does.”
To view the entire paper on Gene-Eden-VIR, visit http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101.
To learn more about Gene-Eden-VIR, visit http://www.gene-eden-kill-virus.com.
###
References:
(1) http://newsdesk.gmu.edu/2013/07/cold-viruses-changing-shape-research-finds/
(2) http://www.medicinenet.com/killer_cold_virus_adenovirus_infection_ad14/page2.htm#what_is_the_killer_cold_virus
(3) http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101
polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.
In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.
polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.
Mike Davis, PolyDNA, http://gene-eden-kill-virus.com/, +1 (585) 250-9999, [email protected]
Share this article